These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
182 related items for PubMed ID: 22796708
1. Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump. Fedorova OV, Kashkin VA, Zakharova IO, Lakatta EG, Bagrov AY. J Hypertens; 2012 Sep; 30(9):1817-26. PubMed ID: 22796708 [Abstract] [Full Text] [Related]
3. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Bagrov AY, Agalakova NI, Kashkin VA, Fedorova OV. Am J Hypertens; 2009 May; 22(5):559-63. PubMed ID: 19229192 [Abstract] [Full Text] [Related]
4. Silencing of PKG1 Gene Mimics Effect of Aging and Sensitizes Rat Vascular Smooth Muscle Cells to Cardiotonic Steroids: Impact on Fibrosis and Salt Sensitivity. Fedorova OV, Shilova VY, Zernetkina V, Juhasz O, Wei W, Lakatta EG, Bagrov AY. J Am Heart Assoc; 2023 Jun 20; 12(12):e028768. PubMed ID: 37301747 [Abstract] [Full Text] [Related]
5. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. Fedorova OV, Agalakova NI, Talan MI, Lakatta EG, Bagrov AY. J Hypertens; 2005 Aug 20; 23(8):1515-23. PubMed ID: 16003178 [Abstract] [Full Text] [Related]
6. Phorbol diacetate potentiates na(+)-k(+) ATPase inhibition by a putative endogenous ligand, marinobufagenin. Fedorova OV, Dorofeeva NA, Lopatin DA, Lakatta EG, Bagrov AY. Hypertension; 2002 Feb 20; 39(2):298-302. PubMed ID: 11847201 [Abstract] [Full Text] [Related]
7. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. Fedorova OV, Simbirtsev AS, Kolodkin NI, Kotov AY, Agalakova NI, Kashkin VA, Tapilskaya NI, Bzhelyansky A, Reznik VA, Frolova EV, Nikitina ER, Budny GV, Longo DL, Lakatta EG, Bagrov AY. J Hypertens; 2008 Dec 20; 26(12):2414-25. PubMed ID: 19008721 [Abstract] [Full Text] [Related]
8. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism. Bagrov AY, Dmitrieva RI, Dorofeeva NA, Fedorova OV, Lopatin DA, Lakatta EG, Droy-Lefaix MT. J Hypertens; 2000 Feb 20; 18(2):209-15. PubMed ID: 10694190 [Abstract] [Full Text] [Related]
9. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY. Circulation; 2002 Mar 05; 105(9):1122-7. PubMed ID: 11877366 [Abstract] [Full Text] [Related]
10. Effects of cardiotonic steroids on isolated perfused kidney and NHE3 activity in renal proximal tubules. Godinho AN, Costa GT, Oliveira NO, Cardi BA, Uchoa DEA, Silveira ER, Quintas LEM, Noël FG, Fonteles MC, Carvalho KM, Santos CF, Lessa LMA, do Nascimento NRF. Biochim Biophys Acta Gen Subj; 2017 Aug 05; 1861(8):1943-1950. PubMed ID: 28506883 [Abstract] [Full Text] [Related]